Search Clinical Trials in the European Union
Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
841-847 of 847 trials
Focal Epilepsy and Tonic-Clonic EpilepsyConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology
Hereditary Angioedema1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine
Rheumatoid Arthritis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesRheumatology
Non-small Cell Lung Cancer (NSCLC)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology
Episodic Migraine6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology
Human Influenza6-12 monthsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious Diseases
Metastatic Breast Cancer>2 yearsMonitoring phase (IV)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology